Cabaletta Bio, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CABA, updated each market day.
CABA AI Sentiment
AI sees no strong directional signal for Cabaletta Bio, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cabaletta Bio, Inc. Common Stock
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
Sector
Exchange
Market Cap
$352,892,867
Cap Tier
Employees
156
Headquarters
PHILADELPHIA, PA
Listed Since
Oct. 25, 2019
Website
CABA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CABA Volatility
Cabaletta Bio, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
